|View printer-friendly version|
|December 21, 2004 5:26 p.m.|
|Teva Announces Tentative Approval Of Rosiglitazone Maleate Tablets|
Jerusalem, Israel, December 21, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the company's ANDA for Rosiglitazone Maleate Tablets, 2 mg, 4 mg and 8 mg. Final approval is expected upon the resolution of patent litigation.